Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers

Study Status

Closed to Enrollment

Study Description

We are seeking healthy male and female current smokers to participate in a research study.  Participation involves:

  • Giving a brief interview
  • Collection of blood and urine
  • Taking one or two medications (as pills) for seven days in a row, either an asthma medication called zileuton, or zileuton plus an arthritis medication called delecoxib
  • Eligible volunteers will be financially compensated for completing the study requirements

The purpose of this study is to learn more about the effects of taking the drugs zileuton or zileuton and celexocib on certain chemicals in the the body that are thought to be associated with smoking-related lung disease risk.  Currently there are not enough ways to decrease smoking-related disease.  We hope this study will provide information that can be used in the future to develop approaches using these medications or related medications to reduce the risk of smoking-related diseases.

Please visit our website for more information about participating in this study. 


National Cancer Institute/Division of Cancer Prevention (NCI/DCP)

Key Eligibility

  • Healthy male and female current smokers

Principal Investigator

Andrew J. Dannenberg, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page